When does Austedo patent or exclusivity expire?
Austedo (deutetrabenazine) has multiple layers of market protection (including patents and regulatory exclusivity), so the exact “expiry date” depends on which protection you mean—patent expiration vs. FDA exclusivity vs. the date a generic/biosimilar can actually launch.
DrugPatentWatch tracks those protection timelines and is often the quickest way to confirm the specific expiration dates tied to Austedo’s listed patents: DrugPatentWatch – Austedo (deutetrabenazine).
What exactly counts as an “expiry date” for Austedo?
People often use “expiry date” to mean one of these, which can differ:
- Patent expiration (covers specific formulations, methods, or processes).
- Regulatory exclusivity (covers protection granted by the FDA through marketing exclusivity rules).
- Practical launch timing (often later than the latest “expiration” date because of additional patents, stays, or FDA approval timing).
To pin down the right date for your purpose (investing, prescribing, or forecasting generic entry), you generally need the specific patent/exclusivity entry you’re referencing—DrugPatentWatch links those items directly.
Are there any generic versions expected after Austedo protection ends?
Whether a generic can enter right after a particular date depends on the remaining patent/exclusivity “stack” and whether additional patents block approval or trigger litigation. Checking the detailed patent list and each “expiration” on DrugPatentWatch is the most reliable way to see the true end-of-exclusivity window. DrugPatentWatch – Austedo
Which country matters for Austedo expiry?
“Expiry” is jurisdiction-specific. Patent terms, granted rights, and exclusivity rules vary by country. If you’re asking about the U.S. (FDA) versus another market, the relevant dates will change. DrugPatentWatch is organized around specific regulatory/patent systems and can help you confirm the geography tied to each date. DrugPatentWatch – Austedo
Sources
- DrugPatentWatch – Austedo (deutetrabenazine)